Maze Therapeutics Inc. (NASDAQ:MAZE) is among the 10 oversold small cap stocks to buy now.
As of the April 24 closing, the consensus sentiment across the inventory was strongly bullish. It obtained Purchase scores from all 12 analysts who supplied protection. Furthermore, it presents virtually 150% upside potential, based mostly on a median 1-year value goal of $64.45, making it one of the vital enticing small-cap picks.
Pressmaster/Shutterstock.com
The bullish views are additionally backed by the corporate’s newest trial outcomes. Again on March 25, Maze Therapeutics Inc. (NASDAQ:MAZE) revealed encouraging outcomes from the Section 2 HORIZON trial on MZE829, an oral drug inhibiting APOL1, in treating a variety of APOL1-induced kidney illnesses. 12 weeks of administration of the drug caused a 35.6% discount within the imply worth of albumin/creatinine ratio in broad AMKD sufferers, the place 50% of sufferers had a discount exceeding 30%.
Sufferers recognized with FSGS situation recorded a discount in imply worth by 61.8%, whereas these affected by non-diabetic AMKD noticed a discount by 48.6%. There have been no extreme negative effects. Maze intends to maneuver the drug right into a pivotal program. Harold Bernstein, President of R&D and Chief Medical Officer, acknowledged that the outcomes show encouraging proof of idea for the precision medication treating the reason for AMKD.
Maze Therapeutics Inc. (NASDAQ:MAZE) is a developer of small-molecule precision medicines for the therapy of kidney and metabolic diseases. The corporate’s lead packages embody MZE829, APOL1, and MZE782. Moreover, it is usually concerned within the improvement of MZE001. The corporate has agreements with numerous organizations for licensing and commercialization of its merchandise.
Whereas we acknowledge the potential of MAZE as an funding, we imagine sure AI shares provide larger upside potential and carry much less draw back danger. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
